{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:05:52Z","timestamp":1788984352895,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd007751.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000}}],"reference-count":381,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007751.pub3","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T11:38:02Z","timestamp":1689766682000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease"],"prefix":"10.1002","volume":"2023","author":[{"given":"Tess E","family":"Cooper","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claris","family":"Teng","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brydee A","family":"Cashmore","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research; The University of Sydney and The Children's Hospital at Westmead; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Emergency and Organ Transplantation; University of Bari; Bari Italy"},{"name":"Cochrane Kidney and Transplant; Centre for Kidney Research, The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJM199608223350814","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Apperloo","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0002|cit2","first-page":"597","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Curren","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00019053-200220010-00004","article-title":"Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation","volume":"20","author":"Hogan","year":"2002","journal-title":"Pharmacoeconomics"},{"issue":"63","key":"10.1002\/14651858.CD007751.pub3-BIB0004|cit4","first-page":"S63","article-title":"Long-term progression of chronic renal insufficiency in the AIPRI extension study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"52","author":"Locatelli","year":"1997","journal-title":"Kidney International - Supplement"},{"issue":"75","key":"10.1002\/14651858.CD007751.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1046\/j.1523-1755.2000.07507.x","article-title":"The role of underlying nephropathy in the progression of renal disease","volume":"57","author":"Locatelli","year":"2000","journal-title":"Kidney International - Supplement"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007751.pub3-BIB0006|cit6","first-page":"S39","article-title":"Perspectives of ACE inhibition in progressive renal failure [abstract no: 103]","volume":"3","author":"Mann","year":"1997","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0007|cit7","unstructured":"Maschio G Alberti D Janin G Locatelli F Mann J Motolese M The use of benazepril in the treatment of progressive renal disease [abstract] 13th International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain 1995 65"},{"issue":"15","key":"10.1002\/14651858.CD007751.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00005344-199900001-00004","article-title":"Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group","volume":"33 Suppl 1","author":"Maschio","year":"1999","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJM199608223350814","article-title":"Effect of benazepril in chronic renal insufficiency","volume":"335","author":"Maschio","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"41","key":"10.1002\/14651858.CD007751.pub3-BIB0011|cit11","first-page":"5798","article-title":"Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril","volume":"158","author":"Pedersen","year":"1996","journal-title":"Ugeskrift for Laeger"},{"issue":"63","key":"10.1002\/14651858.CD007751.pub3-BIB0012|cit12","first-page":"S159","article-title":"Economic evaluation of benazepril in chronic renal insufficiency","volume":"52","author":"Hout","year":"1997","journal-title":"Kidney International - Supplement"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1756-0500-6-306","article-title":"Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study","volume":"6","author":"Espinel","year":"2013","journal-title":"BMC Research Notes"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1291\/hypres.26.875","article-title":"Differing anti-proteinuric action of candesartan and losartan in chronic renal disease","volume":"26","author":"Matsuda","year":"2003","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.jhh.1001543","article-title":"Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease","volume":"17","author":"Matsuda","year":"2003","journal-title":"Journal of Human Hypertension"},{"issue":"20","key":"10.1002\/14651858.CD007751.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3A","key":"10.1002\/14651858.CD007751.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0002-9149(98)00488-3","article-title":"Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition","volume":"82","author":"Pfeffer","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCULATIONAHA.105.592733","article-title":"Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial","volume":"114","author":"Solomon","year":"2006","journal-title":"Circulation"},{"issue":"Sept","key":"10.1002\/14651858.CD007751.pub3-BIB0019|cit19","first-page":"57A","article-title":"In chronic proteinuric nephropathies ramipril therapy is either life and cost-saving [abstract no: A0309]","volume":"11","author":"Brunetti","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1523-1755.2000.00852.x","article-title":"Renoprotective therapy: how good can it get?","volume":"57","author":"Hebert","year":"2000","journal-title":"Kidney International"},{"issue":"9079","key":"10.1002\/14651858.CD007751.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(97)26036-8","article-title":"Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study","volume":"350","author":"Kramer","year":"1997","journal-title":"Lancet"},{"issue":"9145","key":"10.1002\/14651858.CD007751.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(05)61368-2","article-title":"REIN follow-up trial. Ramipril Efficacy in Nephropathy","volume":"352","author":"Locatelli","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1681\/ASN.2010090969","article-title":"ACE inhibition is renoprotective among obese patients with proteinuria","volume":"22","author":"Mallamaci","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9145","key":"10.1002\/14651858.CD007751.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(05)61369-4","article-title":"REIN follow-up trial. Ramipril Efficacy in Nephropathy","volume":"352","author":"Montagnino","year":"1998","journal-title":"Lancet"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0025|cit25","first-page":"78A","article-title":"In chronic nephropathies dihydropyridine calcium channel blockers (CCBs) have an adverse effect on renal function that is prevented by ace inhibition or tight blood pressure control [abstract]","volume":"9","author":"Perna","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9079","key":"10.1002\/14651858.CD007751.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(05)63539-8","article-title":"Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study","volume":"350","author":"Porter","year":"1997","journal-title":"Lancet"},{"issue":"9069","key":"10.1002\/14651858.CD007751.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0028|cit28","first-page":"193","article-title":"A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies","volume":"4","author":"Remuzzi","year":"1991","journal-title":"Journal of Nephrology"},{"issue":"7130","key":"10.1002\/14651858.CD007751.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bmj.316.7130.504","article-title":"Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes [Erratum in: BMJ 1998 Nov 28;317(7171):1491]","volume":"316","author":"Ruggenenti","year":"1998","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1046\/j.1523-1755.2001.00490.x","article-title":"Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies","volume":"59","author":"Ruggenenti","year":"2001","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1681\/ASN.V105997","article-title":"In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia","volume":"10","author":"Ruggenenti","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.V9112096","article-title":"Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN)","volume":"9","author":"Ruggenenti","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0272-6386(00)70054-0","article-title":"Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury","volume":"35","author":"Ruggenenti","year":"2000","journal-title":"American Journal of Kidney Diseases"},{"issue":"9176","key":"10.1002\/14651858.CD007751.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"9136","key":"10.1002\/14651858.CD007751.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0036|cit36","first-page":"83A","article-title":"Deny ACE inhibitors to proteniuric patients with severe renal insufficiency: is it justified? [abstract no: A0436]","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0037|cit37","first-page":"147A","article-title":"The angiotensin-converting-enzyme (ACE) inhibitor ramipril slows the rate of GFR decline (GFR) and the progression to end stage renal failure (ESRF) in proteinuric, non-diabetic chronic renal diseases [abstract no: A0696]","volume":"8","author":"Ruggenenti","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"63","key":"10.1002\/14651858.CD007751.pub3-BIB0038|cit38","first-page":"S54","article-title":"Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN)","volume":"52","author":"Ruggenenti","year":"1997","journal-title":"Kidney International - Supplement"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007751.pub3-BIB0039|cit39","first-page":"S39","article-title":"The REIN study: in non-diabetic chronic nephropathies urinary protein excretion rate accurately predicts progression to end stage renal failure [abstract no: 105]","volume":"3","author":"Ruggenenti","year":"1997","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN)","volume":"53","author":"Ruggenenti","year":"1998","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","article-title":"Retarding progression of chronic renal disease: the neglected issue of residual proteinuria","volume":"63","author":"Ruggenenti","year":"2003","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1681\/ASN.V11188","article-title":"Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)","volume":"11","author":"Ruggenenti","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"(5 Pt 1)","key":"10.1002\/14651858.CD007751.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/00019053-200119050-00005","article-title":"Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance","volume":"19","author":"Schadlich","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2310\/JIM.0b013e31826741d2","article-title":"Renal protection of losartan 50 mg in normotensive Chinese patients with nondiabetic chronic kidney disease","volume":"60","author":"Shen","year":"2012","journal-title":"Journal of Investigative Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0046|cit46","first-page":"557","article-title":"Baseline characteristics of patients entering the pilot African-American Study of Kidney Disease (Pilot-AASK) [abstract]","volume":"5","author":"Breyer","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/ajkd.1998.v32.pm9669421","article-title":"Creatinine clearance as a measure of GFR in screenees for the African-American Study of Kidney Disease and Hypertension pilot study","volume":"32","author":"Coresh","year":"1998","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0272-6386(97)90125-6","article-title":"Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study","volume":"29","author":"Hall","year":"1997","journal-title":"American Journal of Kidney Diseases"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0197-2456(97)82681-5","article-title":"Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study","volume":"17","author":"Kusek","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0050|cit50","first-page":"395","article-title":"Determinants of minority participant adherence in clinical trials: experience of the African American Study of Kidney Disease and Hypertension (AASK) pilot study [abstract]","volume":"6","author":"Lee","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0051|cit51","first-page":"644","article-title":"Quality of life in the African American Study of Kidney Disease and Hypertension (AASK) pilot study [abstract no: 1522]","volume":"6","author":"Lee","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0052|cit52","first-page":"10A","article-title":"Can nocturnal blood pressure (BP) be lowered in African Americans with hypertensive chronic kidney (CKD)? Results from the ABPM pilot study of the African American Study of Kidney Disease and Hypertension (AASK) [abstract no: TH-FC041]","volume":"20","author":"Rahman","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0053|cit53","first-page":"406","article-title":"Serum creatinine is more precise than creatinine clearance for estimating GFR in African Americans (AA): results from the African American Study of Kidney Disease and Hypertension (AASK) pilot study [abstract no: PO1123]","volume":"6","author":"Toto","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0054|cit54","first-page":"570","article-title":"Recruitment in the African American Study of Kidney Disease and hypertension (AASK) pilot study [abstract]","volume":"5","author":"Whelton","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0197-2456(96)00081-5","article-title":"Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study","volume":"17","author":"Wright","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007751.pub3-BIB0056|cit56","first-page":"365","article-title":"Long term effects of combined therapy with ace-inhibitor and angiotensin II receptor antagonist on non-diabetic nephropathies [abstract no: T265]","volume":"18","author":"Acone","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/ajkd.2002.31392","article-title":"Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels","volume":"39","author":"Agarwal","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1046\/j.1523-1755.2001.00745.x","article-title":"Add-on angiotensin receptor blockade with maximized ACE inhibition","volume":"59","author":"Agarwal","year":"2001","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"F863","DOI":"10.1152\/ajprenal.00385.2002","article-title":"Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade","volume":"284","author":"Agarwal","year":"2003","journal-title":"American Journal of Physiology - Renal Physiology"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1053\/j.ajkd.2005.08.034","article-title":"Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies","volume":"46","author":"Aranda","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0061|cit61","first-page":"68A","article-title":"Differential effects of valsartan (V) and lisinopril (L) on potassium [K+] homeostasis in hypertensive patients with nephropathy [abstract no: A0349]","volume":"10","author":"Bakris","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","article-title":"ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group","volume":"58","author":"Bakris","year":"2000","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0063|cit63","first-page":"280","article-title":"Effect of converting enzyme inhibitors (CEI) on renal function in hypertensive patients with chronic renal failure (CRF) [abstract]","volume":"3","author":"Bianchi","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD007751.pub3-BIB0064|cit64","first-page":"vi262","article-title":"Effects of ramipril and valsartan on proteinuria and renal function in patients with non-diabetic proteinuria [abstract no: SAP089]","volume":"22","author":"Bilic","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0065|cit65","first-page":"1061","article-title":"Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria","volume":"35","author":"Bilic","year":"2011","journal-title":"Collegium Antropologicum"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","article-title":"Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies","volume":"63","author":"Campbell","year":"2003","journal-title":"Kidney International"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0067|cit67","first-page":"82A","article-title":"ACE inhibitors (ACEI), angiotensin II antagonists (ATA) or their combination: how to best renoprotect patients with non diabetic chronic nephropathies? [abstract no: A0432]","volume":"12","author":"Perticucci","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0068|cit68","first-page":"A94","article-title":"Effect of lisinopril on the progression of non-diabetic chronic renal failure [abstract]","volume":"12","author":"Cinotti","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/16.5.961","article-title":"Effect of lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies","volume":"16","author":"Cinotti","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD007751.pub3-BIB0070|cit70","first-page":"203A","article-title":"Baseline b-adrenergic blockade-based differences for the effect of renin-angiotensin blockade for the treatment of non-diabetic hypertensive patients with chronic kidney failure: a COOPERATE-Carvedilol substudy [abstract no: F-PO621]","volume":"15","author":"Nakao","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007751.pub3-BIB0071|cit71","first-page":"377A","article-title":"Baseline proteinuria level and an relative nephroprotective efficacy of combination therapy of angiotensin-converting-enzyme inhibitor and angiotensin-II receptor blocker: subgroup analysis of the COOPERATE Trial [abstract no: F-PO191]","volume":"17","author":"Nakao","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000081953","article-title":"Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy","volume":"24","author":"Nakao","year":"2004","journal-title":"American Journal of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0073|cit73","first-page":"A90","article-title":"Combination therapy of ace inhibitor and A-II receptor antagonist more powerfully retard progression of non-diabetic renal failure than monotherapy of each drug - a multicenter, three year, double-blind, randomized trial in Japan (COOPERATE) [abstract]","volume":"16","author":"Nakao","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007751.pub3-BIB0074|cit74","first-page":"134","article-title":"Is small-dose combination of angiotensin receptor blocker and angiotensin-converting enzyme inhibitor still beneficial in management of CRF?: A six-by-five factorial design prospective study [abstract no: M430]","volume":"18","author":"Nakao","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9352","key":"10.1002\/14651858.CD007751.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial [Erratum in: Lancet. 2003 Apr 5;361(9364):1230] [Retraction in: Lancet. 2009 Oct 10;374(9697):1226; PMID: 19819378]","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007751.pub3-BIB0076|cit76","first-page":"81","article-title":"The antiproteinuric effect of losartan and its relationship to systemic blood pressure and renal haemodynamics in patients with chronic renal failure [abstract no: M111]","volume":"17","author":"Crowe","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0077|cit77","first-page":"481A","article-title":"The antiproteinuric effect of losartan and its relationship to systemic blood pressure and renal haemodynamics in patients with chronic renal failure [abstract no: A2486]","volume":"12","author":"Crowe","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/ndt\/gfg315","article-title":"The antiproteinuric effect of losartan is systemic blood pressure dependent","volume":"18","author":"Crowe","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007751.pub3-BIB0079|cit79","first-page":"365","article-title":"Improvement of proteinuria by candesartan, eprosartan, irbesartan, losartan [abstract no: T267]","volume":"18","author":"Deuber","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ndt\/12.5.945","article-title":"ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure","volume":"12","author":"Dyadyk","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007751.pub3-BIB0081|cit81","first-page":"239","article-title":"Renoprotective effect of high or low dosage of enalapril in progressive chronic nephropathy [abstract no: T181]","volume":"17","author":"Elung-Jensen","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2125.2003.01764.x","article-title":"Blood pressure response to conventional and low-dose enalapril in chronic renal failure","volume":"55","author":"Elung-Jensen","year":"2003","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00228-005-0893-x","article-title":"Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial","volume":"61","author":"Elung-Jensen","year":"2005","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0084|cit84","first-page":"482A","article-title":"Short-term blood pressure response to conventional or low dose enalapril in chronic renal failure [abstract no: A2491]","volume":"12","author":"Flemming","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0085|cit85","first-page":"310","article-title":"Short versus long-acting ace-inhibitors: reduction of proteinuria and changes of renal function in patients with glomerulonephritis and mild renal insufficiency [abstract]","volume":"3","author":"Erley","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0086|cit86","unstructured":"Erley CM Komini E Nicaeus T Braun N Wolf S Risler T Reduction of proteinuria and changes of renal function in patients with glomerulonephritis and mild renal insufficiency: short versus long-acting ace-inhibitors [abstract] 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem, Israel 1993 85 CN-00550645"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-2008-1058666","article-title":"The effect of angiotensin-converting enzyme inhibitors on proteinuria in chronic glomerulonephritis","volume":"119","author":"Erley","year":"1994","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000422927","article-title":"Reduction of proteinuria and changes of renal function in patients with glomerulonephritis and mild renal insufficiency. Short versus long-acting angiotensin-converting enzyme inhibitors","volume":"106","author":"Erley","year":"1994","journal-title":"Contributions to Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0089|cit89","unstructured":"Ekhlas Eid A Nguyen J Delcroix C Moutel M Esnault VL Effect of diuretics after dual blockade of renin-angiotensin-aldosterone system on severe proteinuria [abstract no: T022] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 434 5"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1681\/ASN.2004060505","article-title":"Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents","volume":"16","author":"Esnault","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD007751.pub3-BIB0091|cit91","first-page":"762A","article-title":"Angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) and diuretics for refractory proteinuria [abstract no: SU-PO1030]","volume":"14","author":"Esnault","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007751.pub3-BIB0092|cit92","first-page":"804A","article-title":"An increase in diuretic dosage on top of ACEI and ARB dual blockade better decrease proteinuria than up titration of combined ACEI and ARB [abstract no: SA-PO1097]","volume":"17","author":"Esnault","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/ndt\/gfp776","article-title":"Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration","volume":"25","author":"Esnault","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0094|cit94","first-page":"315A","article-title":"Tolerability of valsartan and effects on renal function in treated hypertensive patients with stable renal insufficiency [abstract no: A1450]","volume":"8","author":"Faulhaber","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0095|cit95","first-page":"643","article-title":"Influence of ACE inhibition on glucose tolerance in patients with stable chronic renal failure","volume":"10","author":"Fliser","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0096|cit96","first-page":"960","article-title":"Influence of ACE inhibition on glucose tolerance in patients with stable chronic renal failure [abstract]","volume":"9","author":"Fliser","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ndt\/gfp547","article-title":"Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease","volume":"25","author":"Frimodt-Moller","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0098|cit98","first-page":"653A","article-title":"Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease [abstract no: SA-PO2371]","volume":"21","author":"Frimodt-Moller","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"e41757","DOI":"10.1371\/journal.pone.0041757","article-title":"Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease--a randomized trial","volume":"7","author":"Frimodt-Moller","year":"2012","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007751.pub3-BIB0100|cit100","first-page":"546A","article-title":"Feasibility of dual blockade of the renin-angiotensin system (RAS) in chronic kidney disease (CKD) stage 3-5 [abstract no: F-PO1928]","volume":"19","author":"Frimodt-Moller","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0101|cit101","first-page":"762A","article-title":"Lack of association between serum osteoprotegerin, osteopontin and fetuin-a levels and the longitudinal changes in arterial stiffness in CKD patients undergoing renin-angiotensin system bloackade [abstract no: SA-PO600]","volume":"26","author":"Lyngso","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000087211","article-title":"Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study","volume":"25","author":"Garg","year":"2005","journal-title":"American Journal of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2125.2000.00103.x","article-title":"Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency","volume":"49","author":"Greenbaum","year":"2000","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3317\/jraas.2001.039","article-title":"Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension","volume":"2","author":"Hannedouche","year":"2001","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ki.1996.24","article-title":"Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition","volume":"49","author":"Hemmelder","year":"1996","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0106|cit106","first-page":"331","article-title":"Role of systemic and renal hemodynamics in the antiproteinuric effect of acute ace-inhibition (ACEi) [abstract]","volume":"5","author":"Hemmelder","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.jhh.1001761","article-title":"Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease","volume":"18","author":"Homma","year":"2004","journal-title":"Journal of Human Hypertension"},{"issue":"9200","key":"10.1002\/14651858.CD007751.pub3-BIB0108|cit108","first-page":"253","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [Erratum in: Lancet 2000 Sep 2;356(9232):860]","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/diacare.19.11.1225","article-title":"Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation","volume":"19","author":"Gerstein","year":"1996","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00125-005-1858-4","article-title":"The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis","volume":"48","author":"Gerstein","year":"2005","journal-title":"Diabetologia"},{"issue":"117","key":"10.1002\/14651858.CD007751.pub3-BIB0111|cit111","first-page":"8","article-title":"Diabetes and the HOPE study: implications for macrovascular and microvascular disease","author":"Gerstein","year":"2001","journal-title":"International Journal of Clinical Practice. Supplement"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM200001203420302","article-title":"Vitamin E supplementation and cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0113|cit113","first-page":"145","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. [Erratum in: 2000 May 4;342(18):1376] [Erratum in: N Engl J Med 2000 Mar 9;342(10):748]","volume":"342","author":"Yusuf","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3949\/ccjm.67.4.287","article-title":"The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not","volume":"67","author":"Hoogwerf","year":"2000","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.CIR.0000050600.49419.25","article-title":"Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study","volume":"107","author":"Lamy","year":"2003","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007751.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"291A","DOI":"10.1016\/S0735-1097(02)81305-5","article-title":"Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients [abstract no: 1051-29]","volume":"39","author":"Lonn","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/01.hjr.0000106836.977722.cf","article-title":"Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients","volume":"10","author":"Lonn","year":"2003","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"issue":"5 Suppl 2","key":"10.1002\/14651858.CD007751.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0735-1097(02)81304-3","article-title":"Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial [abstract no: 1051-28]","volume":"39","author":"Lonn","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2337\/diacare.25.11.1919","article-title":"Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy","volume":"25","author":"Lonn","year":"2002","journal-title":"Diabetes Care"},{"issue":"Sept","key":"10.1002\/14651858.CD007751.pub3-BIB0120|cit120","first-page":"156A","article-title":"Renal insufficiency (RI) as predicator of cardiovascular (CV) outcomes and impact of ramipril: the HOPE study [abstract no: A0836]","volume":"11","author":"Mann","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ajkd.2003.07.015","article-title":"Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study","volume":"42","author":"Mann","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.ASN.0000051594.21922.99","article-title":"Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study","volume":"14","author":"Mann","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1523-1755.2004.00513.x","article-title":"Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study","volume":"65","author":"Mann","year":"2004","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CNP63181","article-title":"Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study","volume":"63","author":"Mann","year":"2005","journal-title":"Clinical Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD007751.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/hc3901.096700","article-title":"Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril","volume":"104","author":"Mathew","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00365510500236366","article-title":"The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences","volume":"240","author":"McQueen","year":"2005","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation Supplement"},{"issue":"9299","key":"10.1002\/14651858.CD007751.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0140-6736(01)07186-0","article-title":"Blood-pressure reduction and cardiovascular risk in HOPE study","volume":"358","author":"Sleight","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.0000044940.65226.1F","article-title":"Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study","volume":"107","author":"Smieja","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0130|cit130","first-page":"127","article-title":"The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators","volume":"12","year":"1996","journal-title":"Canadian Journal of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD007751.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1161\/01.CIR.0000038890.39298.8D","article-title":"Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events","volume":"106","author":"Veres","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0133|cit133","first-page":"284","article-title":"The effect of angiotensin converting enzyme inhibition (ACEi) on progression of chronic renal insufficiency (CRI) [abstract]","volume":"3","author":"Ihle","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0272-6386(96)90158-4","article-title":"Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial","volume":"27","author":"Ihle","year":"1996","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0135|cit135","first-page":"251","article-title":"Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure [abstract]","volume":"4","author":"Kamper","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0136|cit136","first-page":"672","article-title":"Randomised controlled trial of enalapril in progressive chronic renal failure [abstract]","volume":"5","author":"Kamper","year":"1990","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0137|cit137","first-page":"829","article-title":"Randomised controlled trial of enalapril in progressive chronic renal failure [abstract]","volume":"5","author":"Kamper","year":"1990","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0138|cit138","first-page":"1321","article-title":"The validity of doubling of plasma creatinine (Pcrea) as a marker of progression of chronic renal failure [abstract no: A0375]","volume":"7","author":"Kamper","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0272-6386(96)90381-9","article-title":"The influence of angiotensin-converting enzyme inhibition on renal tubular function in progressive chronic nephropathy","volume":"28","author":"Kamper","year":"1996","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/00365519009089178","article-title":"Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy","volume":"50","author":"Kamper","year":"1990","journal-title":"Scandinavian Journal of Clinical & Laboratory Investigation"},{"issue":"31","key":"10.1002\/14651858.CD007751.pub3-BIB0141|cit141","first-page":"2406","article-title":"Angiotensin I converting enzyme inhibitor enalapril in treatment of progressive chronic nephropathy. An open randomized controlled trial","volume":"155","author":"Kamper","year":"1993","journal-title":"Ugeskrift for Laeger"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ajh\/5.7.423","article-title":"Effect of enalapril on the progression of chronic renal failure","volume":"5","author":"Kamper","year":"1992","journal-title":"American Journal of Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/ndt\/10.7.1182","article-title":"Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria","volume":"10","author":"Kamper","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0144|cit144","unstructured":"Kamper AL Strandgaard S Leyssac PP Randomized controlled trial of enalapril in progressive chronic renal failure [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 9A"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2215\/CJN.01110905","article-title":"Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors","volume":"1","author":"Kanno","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0146|cit146","first-page":"105A","article-title":"Add-on angiotensin receptor blocker in patients with chronic kidney diseases treated with angiotensin converting enzyme inhibitors [abstract no: SA-FC104]","volume":"16","author":"Kanno","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"246","DOI":"10.7326\/0003-4819-118-4-199302150-00002","article-title":"Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor","volume":"118","author":"Keilani","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"20","key":"10.1002\/14651858.CD007751.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9149(93)91053-K","article-title":"Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril","volume":"72","author":"Schlueter","year":"1993","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0149|cit149","unstructured":"Kim HJ Han SW No more aggravation of hyperkalemia by the combined therapy of angiotensin II receptor antagonist and angiotensin converting enzyme inhibitor in renal diseases than either therapy alone [abstract no: FP.8.4] 13th Asian Colloquium in Nephrology; 2000 Nov 23-25; Bali, Indonesia 2000"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0150|cit150","first-page":"75A","article-title":"Comparison of the effect of 50% increase in angiotensin converting enzyme inhibitor (ACEI) with a combination of candesartan and ACEI on proteinuria and blood pressure in chronic renal disease [abstract no: A0392]","volume":"12","author":"Kincaid-Smith","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007751.pub3-BIB0151|cit151","first-page":"A25","article-title":"Comparison of the effect of 50% increase in angiotensin converting enzyme inhibitor (ACEI) with a combination of candesartan and ACEI on proteinuria and blood pressure in chronic renal disease [abstract no: P99]","volume":"7","author":"Kincaid-Smith","year":"2002","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/ndt\/17.4.597","article-title":"Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria","volume":"17","author":"Kincaid-Smith","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007751.pub3-BIB0153|cit153","first-page":"131","article-title":"A fall in urine protein with combined angiotensin converting enzyme inhibitor (ACEI) and aII receptor antagonist (AIIRA) treatment predicts a good outcome at three years in patients with chronic renal disease with continuing reduction in urine protein levels. Diabetic and obese patients with a poor response to combined ACEI and AIIRA treatment have a poor outcome [abstract no: M419]","volume":"18","author":"Kincaid-Smith","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Sept","key":"10.1002\/14651858.CD007751.pub3-BIB0154|cit154","first-page":"349A","article-title":"Randomised controlled crossover study of the effect on proteinuria of adding an angiotensin 11-receptor antagonist (ARA) to an angiotensin converting enzyme inhibitor (ACEi) [abstract no: A1825]","volume":"11","author":"Kincaid-Smith","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD007751.pub3-BIB0155|cit155","first-page":"786A","article-title":"A fall in urine protein with combined angiotensin converting enzyme inhibitor (ACEI) and AII receptor antagonist (AIIRA) treatment predicts a good outcome at three years in patients with chronic renal disease (mean serum creatinine level of 0.18 mmols\/litre mean urinary protein level of 2.3 grams\/24 hours). Diabetic and obese patients with poor response to combined ACEI and AIIRA treatment have a poor outcome [abstract no: PUB059]","volume":"14","author":"Kincaid-Smith","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.ASN.0000045049.72965.B7","article-title":"Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure","volume":"14","author":"Klein","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD007751.pub3-BIB0157|cit157","first-page":"349A","article-title":"Enalapril and losartan are equally effective in reducing sympathetic hyperactivity [abstract no: A1826]","volume":"11","author":"Klein","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1032","key":"10.1002\/14651858.CD007751.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/pgmj.2011.118059","article-title":"Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease","volume":"87","author":"Lee","year":"2011","journal-title":"Postgraduate Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0159|cit159","first-page":"446","article-title":"Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO)","volume":"24","author":"Maione","year":"2007","journal-title":"Giornale Italiano di Nefrologia"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0160|cit160","first-page":"646","article-title":"Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial","volume":"20","author":"Maione","year":"2007","journal-title":"Journal of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1681\/ASN.2018040443","article-title":"The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A randomized, controlled trial","volume":"29","author":"Saglimbene","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0162|cit162","first-page":"103","article-title":"ACE inhibitor, ARB, or combined therapy in patients with diabetes and microalbuminuria: the long-term impact of RAS inhibition on cardiorenal outcomes (LIRICO) randomized clinical trial [abstract no: SA-OR115]","volume":"28","author":"Strippoli","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0163|cit163","first-page":"c139","article-title":"A prospective open-label randomised trial of quinapril and\/or amlodipine in progressive non-diabetic renal failure","volume":"101","author":"MacGregor","year":"2005","journal-title":"Nephron"},{"issue":"Nov","key":"10.1002\/14651858.CD007751.pub3-BIB0164|cit164","first-page":"443A","article-title":"A prospective open-label randomized trial of quinapril and\/or amlodipine in progressive non-diabetic renal failure [abstract no: SA-PO667]","volume":"14","author":"MacGregor","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0165|cit165","first-page":"443A","article-title":"Effect of ACE inhibition on hemoglobin in chronic renal failure: a randomized controlled trial [abstract no: SA-PO666]","volume":"14","author":"MacGregor","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0166|cit166","first-page":"A150","article-title":"Antihypertensive therapy and progression of renal failure in hypertensive nephropathy (HN) [abstract]","volume":"14","author":"Marcantoni","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0167|cit167","first-page":"75A","article-title":"Antihypertensive therapy and progression of renal failure in hypertensive nephropathy (HN) [abstract no: S124]","volume":"9","author":"Marcantoni","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0168|cit168","unstructured":"Meier P Maillard M Meier R Burnier M Antiproteinuric effect of losartan: is a higher dose as effective as an association with an ACE inhibitor? Results of a randomised triple-crossover study in proteinuric patients [abstract no: F-PO1920] Journal of the American Society of Nephrology 2008 19 543A"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0169|cit169","unstructured":"Meier P Maillard M Tremblay S Meier R Burnier M Comparative 24h blood pressure effects of increasing doses of losartan and the association of losartan and an ACE inhibitor in proteinuric patients [abstract no: SA-PO2249] Journal of the American Society of Nephrology 2008 19 617A"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/HJH.0b013e328346d5dc","article-title":"Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study","volume":"29","author":"Meier","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"Sept","key":"10.1002\/14651858.CD007751.pub3-BIB0171|cit171","first-page":"619A","article-title":"Acute and long-term effects of 2 different ACE inhibitors on renal hemodynamics [abstract]","volume":"11","author":"Guidi","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/10.supp6.18","article-title":"Long versus short-term effects of two different ACE inhibitors on renal haemodynamics: preliminary results from an ongoing trial","volume":"10 Suppl 6","author":"Minetti","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0272-6386(97)90464-9","article-title":"Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency","volume":"29","author":"Mitchell","year":"1997","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007751.pub3-BIB0174|cit174","first-page":"S112","article-title":"The NEPHROS study - effects of an ACE inhibitor, a calcium channel blocker, or their combination on progression of renal impairment [abstract]","volume":"124","author":"Bader","year":"1999","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/ndt\/16.11.2158","article-title":"The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study","volume":"16","author":"Herlitz","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","article-title":"Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies","volume":"10","author":"Anderson","year":"2011","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2215\/CJN.06640712","article-title":"Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures","volume":"8","author":"Barzilay","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: The ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCULATIONAHA.109.864199","article-title":"Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/TRANSCEND) Trials","volume":"121","author":"Bohm","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ahj.2013.04.016","article-title":"Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease","volume":"166","author":"Bohm","year":"2013","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.diabres.2008.12.005","article-title":"Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET\/TRANSCEND research programme","volume":"83","author":"Cukierman-Yaffe","year":"2009","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"e13694","DOI":"10.1371\/journal.pone.0013694","article-title":"In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events","volume":"5","author":"Dans","year":"2010","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"23","key":"10.1002\/14651858.CD007751.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1161\/CIRCULATIONAHA.112.103234","article-title":"Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries","volume":"126","author":"Dehghan","year":"2012","journal-title":"Circulation"},{"issue":"18","key":"10.1002\/14651858.CD007751.pub3-BIB0185|cit185","first-page":"1682","article-title":"Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus","volume":"173","author":"Dunkler","year":"2013","journal-title":"JAMA Internal Medicine"},{"issue":"9655","key":"10.1002\/14651858.CD007751.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)61860-7","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Gallieni","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/2047487313510678","article-title":"The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial","volume":"21","author":"Heerspink","year":"2014","journal-title":"European Journal of Preventive Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.111.086660","article-title":"Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)","volume":"126","author":"Kappert","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00392-013-0644-4","article-title":"Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET\/TRANSCEND","volume":"103","author":"Lonn","year":"2014","journal-title":"Clinical Research in Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/HYPERTENSIONAHA.112.199562","article-title":"Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)","volume":"60","author":"Mancia","year":"2012","journal-title":"Hypertension"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/HJH.0000000000002567","article-title":"Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials","volume":"38","author":"Mancia","year":"2020","journal-title":"Journal of Hypertension"},{"issue":"16","key":"10.1002\/14651858.CD007751.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/CIRCULATIONAHA.110.008870","article-title":"Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)","volume":"124","author":"Mancia","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/HJH.0b013e32835bf7b0","article-title":"Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial","volume":"31","author":"Mann","year":"2013","journal-title":"Journal of Hypertension"},{"issue":"9638","key":"10.1002\/14651858.CD007751.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007751.pub3-BIB0195|cit195","first-page":"48A","article-title":"Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk: results from the ONTARGET trial [abstract no: F-FC209]","volume":"19","author":"Mann","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9655","key":"10.1002\/14651858.CD007751.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(08)61863-2","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Narayanan","year":"2008","journal-title":"Lancet"},{"issue":"9655","key":"10.1002\/14651858.CD007751.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(08)61861-9","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Nonoguchi","year":"2008","journal-title":"Lancet"},{"issue":"15","key":"10.1002\/14651858.CD007751.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","article-title":"Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)","volume":"59","author":"Redon","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0200|cit200","first-page":"1","article-title":"Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme","volume":"3","author":"Ruilope","year":"2007","journal-title":"Vascular Health & Risk Management"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD007751.pub3-BIB0201|cit201","first-page":"309A","article-title":"ONTARGET: cardiovascular outcome in patients at high cardiovascular risk and with chronic kidney disease (CKD) [abstract no: TH-PO886]","volume":"19","author":"Schmieder","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/HJH.0b013e32832d7370","article-title":"Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study","volume":"27","author":"Sleight","year":"2009","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.hjh.0000357905.78704.9a","article-title":"Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor","volume":"27","author":"Sleight","year":"2009","journal-title":"Journal of Hypertension - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","article-title":"Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials","volume":"148","author":"Teo","year":"2004","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/HJH.0b013e3283522a51","article-title":"Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies","volume":"30","author":"Verdecchia","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"14","key":"10.1002\/14651858.CD007751.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.109.865774","article-title":"Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease","volume":"120","author":"Verdecchia","year":"2009","journal-title":"Circulation"},{"issue":"9655","key":"10.1002\/14651858.CD007751.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(08)61862-0","article-title":"Renal outcomes in the ONTARGET study","volume":"372","author":"Wetzels","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0209|cit209","first-page":"1763","article-title":"Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data","volume":"124","author":"Yu","year":"2011","journal-title":"Chinese Medical Journal"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007751.pub3-BIB0210|cit210","first-page":"iv341","article-title":"Effect of angiotensin converting enzyme inhibitors and angiotensin Type I receptor antagonists on plasminogen activator inhibitor - 1 levels in patients with hypertensive nephrosclerosis [abstract no: MP127]","volume":"21","author":"Papadogiannakis","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2165\/00044011-199714040-00002","article-title":"Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency","volume":"14","author":"Perico","year":"1997","journal-title":"Clinical Drug Investigation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0212|cit212","first-page":"320A","article-title":"Valsartan, a new angiotensin II receptor antagonist for the treatment of hypertension: efficacy and safety compared to lisinopril in patients with stable renal insufficiency [abstract no: A1474]","volume":"9","author":"Perico","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.V9122223","article-title":"Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension","volume":"9","author":"Plum","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ndt\/14.suppl_4.25","article-title":"Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension","volume":"14 Suppl 4","author":"Plum","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007751.pub3-BIB0215|cit215","first-page":"S49","article-title":"Combined treatment with an angiotensin II receptor antagonist and an ACE inhibitor in patients with proteinuria hypertension [abstract no: P3-8]","volume":"125","author":"Plum","year":"2000","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ndt\/gfg623","article-title":"Anti-proteinuric effect of losartan: statistical vs clinical significance (multiple letters)","volume":"19","author":"Ghosh","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0217|cit217","first-page":"3A","article-title":"Antiproteinuric effect of losartan in nondiabetic proteinuric renal diseases: a double blind, randomized clinical trial [abstract no: F-FC013]","volume":"13","author":"Praga","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/ndt\/gfg284","article-title":"Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial","volume":"18","author":"Praga","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.hjh.0000226212.34055.86","article-title":"Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial","volume":"24","author":"Arima","year":"2006","journal-title":"Journal of Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1161\/01.STR.0000221212.36860.c9","article-title":"Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial","volume":"37","author":"Arima","year":"2006","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/08037050410029605","article-title":"Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial","volume":"13","author":"Berthet","year":"2004","journal-title":"Blood Pressure"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/01.STR.0000106480.76217.6F","article-title":"Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial","volume":"35","author":"Chapman","year":"2004","journal-title":"Stroke"},{"issue":"12 Pt 2","key":"10.1002\/14651858.CD007751.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1097\/00004872-199512010-00068","article-title":"PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee [corrected] [Erratum in: J Hypertens 1996 Apr;14(4):535]","volume":"13","author":"Neal","year":"1995","journal-title":"Journal of Hypertension"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/ki.2008.5","article-title":"Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial","volume":"73","author":"Ninomiya","year":"2008","journal-title":"Kidney International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007751.pub3-BIB0225|cit225","first-page":"A31","article-title":"The efficacy of lower blood pressure goals on the prevention of stroke in chronic kidney disease: data from the PROGRESS study [abstract no: 1122]","volume":"12","author":"Ninomiya","year":"2007","journal-title":"Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007751.pub3-BIB0226|cit226","first-page":"11A","article-title":"Lower blood pressure goals and the risk of stroke in chronic kidney disease: data from the PROGRESS study [abstract no: F-FC048]","volume":"18","author":"Ninomiya","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9287","key":"10.1002\/14651858.CD007751.pub3-BIB0227|cit227","first-page":"1033","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack [Erratum in: Lancet 2001 Nov 3;358(9292):1556] [Erratum in: Lancet 2002 Jun 15;359(9323):2120]","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007751.pub3-BIB0228|cit228","first-page":"192A","article-title":"Predictive ability of different measures of kidney function: data from the PROGRESS study [abstract no: TH-PO401]","volume":"17","author":"Perkovic","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007751.pub3-BIB0229|cit229","first-page":"A21","article-title":"Reductions in the risks of vascular events and stroke in patients with and without chronic kidney disease; new data from the PROGRESS trial [abstract no: 1571]","volume":"11","author":"Perkovic","year":"2006","journal-title":"Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007751.pub3-BIB0230|cit230","first-page":"809A","article-title":"The cardiovascular effects of perindopril based therapy in CKD: data from the PROGRESS study [abstract no: SA-PO1122]","volume":"17","author":"Perkovic","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007751.pub3-BIB0231|cit231","first-page":"A46","article-title":"The predictive ability of different measures of kidney function: new data from the PROGRESS study [abstract no: 2542]","volume":"11","author":"Perkovic","year":"2006","journal-title":"Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1681\/ASN.2007020256","article-title":"Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study","volume":"18","author":"Perkovic","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0233|cit233","first-page":"852","article-title":"Therapeutic safety of perindopril in the treatment of mild hypertension with concomitant nephropathy","volume":"43","author":"Bonner","year":"1993","journal-title":"Arzneimittel-Forschung"},{"issue":"17","key":"10.1002\/14651858.CD007751.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0002-9149(93)90950-H","article-title":"A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS)","volume":"71","author":"Stumpe","year":"1993","journal-title":"American Journal of Cardiology"},{"issue":"4B","key":"10.1002\/14651858.CD007751.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0002-9343(92)90157-7","article-title":"Angiotensin-converting enzyme inhibition in mild hypertension with concomitant diseases and therapies: an efficacy, safety, and compatibility study of novel design, the Perindopril Therapeutic Safety Study","volume":"92","author":"Stumpe","year":"1992","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007751.pub3-BIB0237|cit237","first-page":"808A","article-title":"Renoprotection of optimal antiproteinuric doses of benazepril and losartan in chronic renal insufficiency [abstract no: SA-PO1118]","volume":"17","author":"Hou","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/0091270010377502","article-title":"High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease","volume":"51","author":"Xie","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0239|cit239","first-page":"75A","article-title":"Safety of the combination of valsartan (V) and benazepril (BZ) in patients with chronic renal disease (CRD) [abstract no: A0361]","volume":"8","author":"Ruilope","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004872-200018010-00013","article-title":"Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease","volume":"18","author":"Ruilope","year":"2000","journal-title":"Journal of Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0241|cit241","first-page":"25","article-title":"Angiotensin II receptor blockade in comparison to ACE inhibition in patients with chronic kidney failure","volume":"3","author":"Rump","year":"1999","journal-title":"Journal fur Hypertonie"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0242|cit242","unstructured":"Renke M Tylicki L Ruthkowski P Wonjnarowski K Lysiak-Szydlowska W Rutkowski B Low-dose dual blockade of the renin-angiotensin system improves tubular status in nondiabetic proteinuric patients [abstract no: MP093] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 260"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/00365590510031264","article-title":"Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients","volume":"39","author":"Renke","year":"2005","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.ajkd.2003.10.032","article-title":"Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis","volume":"43","author":"Rutkowski","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-8703(98)70315-1","article-title":"Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement","volume":"135","author":"Hager","year":"1998","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1681\/ASN.2006010063","article-title":"Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction","volume":"17","author":"Jose","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM199207233270405","article-title":"Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators","volume":"327","author":"Lamas","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1161\/01.CIR.96.12.4254","article-title":"Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement","volume":"96","author":"Mitchell","year":"1997","journal-title":"Circulation"},{"issue":"14","key":"10.1002\/14651858.CD007751.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0002-9149(91)90263-K","article-title":"Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. SAVE Investigators","volume":"68","author":"Moye","year":"1991","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.1991.03470040092028","article-title":"Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators","volume":"266","author":"Pfeffer","year":"1991","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJM199303183281108","article-title":"A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators","volume":"328","author":"Rouleau","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1161\/01.CIR.90.4.1731","article-title":"Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators","volume":"90","author":"Rutherford","year":"1994","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/14651858.CD007751.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1161\/01.CIR.0000149806.01354.BF","article-title":"Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study","volume":"110","author":"Tokmakova","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0735-1097(98)00533-6","article-title":"Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement","volume":"33","author":"Urena","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0735-1097(96)00489-5","article-title":"Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators","volume":"29","author":"Vantrimpont","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/01.hjh.0000160225.01845.26","article-title":"Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial","volume":"23","author":"Scaglione","year":"2005","journal-title":"Journal of Hypertension"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007751.pub3-BIB0258|cit258","first-page":"133","article-title":"The effect of treatment with ultra high dose candesartan (64 mg) on proteinuria: interim results of a double-blind, randomized, multi-center study [abstract no: P1782]","volume":"18","author":"Fleischmann","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007751.pub3-BIB0259|cit259","first-page":"A244","article-title":"Additive effect of ultra high dose (64 mg) candesartan on proteinuria: a double blind randomized study [abstract no: W-PO20003]","volume":"10","author":"Schmieder","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007751.pub3-BIB0260|cit260","first-page":"v69","article-title":"Dose-response effect of angiotensin receptor blocker candesartan on proteinuria: a double blind, randomized study [abstract no: SP149]","volume":"20","author":"Schmieder","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD007751.pub3-BIB0261|cit261","first-page":"119A","article-title":"Additional antiproteinuric effect of ultra high dose (64mg) candesartan: a double blind, randomized study. [abstract no: F-P0243]","volume":"15","author":"Schmieder","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","article-title":"Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study","volume":"16","author":"Schmieder","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0263|cit263","first-page":"A69","article-title":"A randomized, double-blind, parallel study of the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function [abstract]","volume":"14","author":"Schulz","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ndt\/14.suppl_4.27","article-title":"A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function","volume":"14 Suppl 4","author":"Schulz","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007751.pub3-BIB0265|cit265","first-page":"S107","article-title":"A randomized, double-blind, parallel study of the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function [abstract]","volume":"124","author":"Schulz","year":"1999","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"1067 Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0266|cit266","first-page":"165","article-title":"Comparative study of losartan and enalapril on haemorrheology in patients with renal disease and hypertension [abstract]","volume":"111","author":"Shand","year":"1998","journal-title":"New Zealand Medical Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007751.pub3-BIB0267|cit267","first-page":"S517","article-title":"Comparative study between losartan and enalapril on renal function, blood pressure and haematology in patients with renal disease and hypertension [abstract no: P1782]","volume":"3","author":"Shand","year":"1997","journal-title":"Nephrology"},{"issue":"1-2 Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0268|cit268","first-page":"A8","article-title":"Comparative study of the effects of enalapril and losartan on glomerular size selectivity in patients with proteinuria [abstract no: 22]","volume":"5","author":"Shand","year":"2000","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.jhh.1001011","article-title":"Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension","volume":"14","author":"Shand","year":"2000","journal-title":"Journal of Human Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2169\/internalmedicine.45.1515","article-title":"A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy","volume":"45","author":"Shoda","year":"2006","journal-title":"Internal Medicine"},{"issue":"Oct","key":"10.1002\/14651858.CD007751.pub3-BIB0271|cit271","first-page":"130a","article-title":"Angiotensin converting enzyme inhibitor (ACE) versus angiotensin receptor blocker (ARB): a five-year comparison of renal survival and effects on blood pressure, creatinine clearance, urinary protein excretion [abstract no: F-PO293]","volume":"15","author":"Shoda","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"Supramaximal dose of candesartan in proteinuric renal disease","volume":"20","author":"Burgess","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007751.pub3-BIB0273|cit273","first-page":"57A","article-title":"A double-blind randomized controlled trial of high dose candesartan cilexetil in proteinuric renal disease - results from SMART (Supra Maximal Atacand Renal Trial) [abstract no: SA-FC104]","volume":"18","author":"Burgess","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD007751.pub3-BIB0274|cit274","first-page":"357A","article-title":"A randomised controlled trial of high dose candesartan in the treatment of proteinuric renal disease: design and baseline characteristics [abstract no: SA-PO261]","volume":"15","author":"Muirhead","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0275|cit275","unstructured":"Takagi N Tokita Y Takeda K Ueda S Abe Y Yabana M Effect of long-term administration of angiotensin converting enzyme inhibitors on renal function in hypertensive patients associated with renal failure [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 321A"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0276|cit276","first-page":"341","article-title":"Rampril reduces proteinuria in normotensive non-diabetic renal disease: a prospective double-blind randomized trial [abstract]","volume":"5","author":"Smith","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0272-6386(96)90382-0","article-title":"Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria","volume":"28","author":"Toto","year":"1996","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","article-title":"Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies","volume":"10","author":"Anderson","year":"2011","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2215\/CJN.06640712","article-title":"Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures","volume":"8","author":"Barzilay","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinternmed.2010.502","article-title":"Albuminuria and decline in cognitive function: the ONTARGET\/TRANSCEND studies","volume":"171","author":"Barzilay","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/dc11-0545","article-title":"Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study","volume":"34","author":"Barzilay","year":"2011","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCULATIONAHA.109.864199","article-title":"Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET\/TRANSCEND) Trials","volume":"121","author":"Bohm","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.diabres.2008.12.005","article-title":"Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET\/TRANSCEND research programme","volume":"83","author":"Cukierman-Yaffe","year":"2009","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"e13694","DOI":"10.1371\/journal.pone.0013694","article-title":"In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events","volume":"5","author":"Dans","year":"2010","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"23","key":"10.1002\/14651858.CD007751.pub3-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1161\/CIRCULATIONAHA.112.103234","article-title":"Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries","volume":"126","author":"Dehghan","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.106.661405","article-title":"Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk","volume":"115","author":"Held","year":"2007","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.111.086660","article-title":"Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)","volume":"126","author":"Kappert","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/HJH.0000000000002567","article-title":"Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials","volume":"38","author":"Mancia","year":"2020","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0290|cit290","unstructured":"Mann J Schmieder R Dyal L Schumacher H Dagenais G Teo K Renal outcomes with telmisartan in 5926 people at high vascular risk, results of the TRANSCEND study, a randomised placebo controlled trial [abstract no: SA777] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial [summary for patients in Ann Intern Med. 2009 Jul 7;151(1):I28; PMID: 19451555]","volume":"151","author":"Mann","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0292|cit292","first-page":"707A","article-title":"A gene variant in the CERS2 gene is associated with worsening albuminuria in diabetic patients of ONTARGET and TRANSCEND [abstract no: SA-PO351]","volume":"24","author":"Shiffman","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9644","key":"10.1002\/14651858.CD007751.pub3-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial [Erratum in: Lancet. 2008 Oct 18;372(9647):1384]","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","article-title":"Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials","volume":"148","author":"Teo","year":"2004","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/HJH.0b013e3283522a51","article-title":"Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial\/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies","volume":"30","author":"Verdecchia","year":"2012","journal-title":"Journal of Hypertension"},{"issue":"14","key":"10.1002\/14651858.CD007751.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.109.865774","article-title":"Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease","volume":"120","author":"Verdecchia","year":"2009","journal-title":"Circulation"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD007751.pub3-BIB0298|cit298","first-page":"vi259","article-title":"The triple renin-angiotensin-aldosterone system blockade - new promising nephroprotective strategy in patients with proteinuric nondiabetic renal disease [abstract no: SA-PO81]","volume":"22","author":"Larczynski","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/sj.ki.5002511","article-title":"Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney","volume":"72","author":"Tylicki","year":"2007","journal-title":"Kidney International"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007751.pub3-BIB0301|cit301","first-page":"iv334","article-title":"The influence of very high dosage of cilazapril on proteinuria during dual renin-angiotensin-aldosteron system blockade in patients with proteinuric nondiabetic renal disease [abstract no: MP106]","volume":"21","author":"Larczynski","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/ndt\/gfn665","article-title":"High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease","volume":"24","author":"Renke","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/00365590801905943","article-title":"Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study","volume":"42","author":"Tylicki","year":"2008","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD007751.pub3-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/HJH.0b013e32830508aa","article-title":"Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial","volume":"26","author":"Menne","year":"2008","journal-title":"Journal of Hypertension"},{"issue":"38","key":"10.1002\/14651858.CD007751.pub3-BIB0305|cit305","first-page":"156","article-title":"Changing the trandolapril dosage regimen does not affect the proteinuria-lowering effect of ACE inhibition in non-diabetic renal disease","volume":"144","author":"Van Der Wouden","year":"2009","journal-title":"Pharmaceutisch Weekblad"},{"issue":"Suppl A","key":"10.1002\/14651858.CD007751.pub3-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1097\/01.hjh.0000379394.19544.fc","article-title":"Optimal dosing time for the long-acting ace inhibitor trandolapril in non-diabetic kidney disease","volume":"28","author":"Vogt","year":"2010","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0307|cit307","first-page":"783A","article-title":"Altered dosing of trandolapril does not overcome nocturnal resistance to the antiproteinuric effect of ACE inhibition in non-diabetic renal disease [abstract no: SA-PO1036]","volume":"16","author":"Wouden","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0308|cit308","first-page":"532A","article-title":"Lower renal function is associated with higher aldosterone and high blood pressure in chronic kidney disease, irrespective of RAAS inhibition [abstract no: FR-PO726]","volume":"27","author":"Gant","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12882-017-0789-x","article-title":"Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels","volume":"18","author":"Gant","year":"2017","journal-title":"BMC Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14728220902905865","article-title":"Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin","volume":"13","author":"Krikken","year":"2009","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1111\/j.1538-7836.2011.04525.x","article-title":"The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria","volume":"9","author":"Mahmoodi","year":"2011","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/ndt\/gfr402","article-title":"Vascular endothelial growth factor C levels are modulated by dietary salt intake in proteinuric chronic kidney disease patients and in healthy subjects","volume":"27","author":"Slagman","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2215\/CJN.08190910","article-title":"Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF\/CCN-2) plasma and urine levels in nondiabetic nephropathy","volume":"6","author":"Slagman","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1093\/ndt\/gfq149","article-title":"Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function","volume":"25","author":"Slagman","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/ndt\/gfr408","article-title":"Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients","volume":"27","author":"Slagman","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0317|cit317","first-page":"37A","article-title":"Independent and added effects of low sodium and diuretic on renoprotective effect of AII antagonist in non-diabetic proteinuric patients [abstract no: TH-FC171]","volume":"16","author":"Vogt","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2008.07.021","article-title":"Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and\/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial","volume":"53","author":"Waanders","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD007751.pub3-BIB0319|cit319","first-page":"546A","article-title":"Specific antiproteinuric benefit of sodium depletion in non-diabetic patients resistant to RAS-blockade [abstract no: SA-PO922]","volume":"18","author":"Waanders","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007751.pub3-BIB0320|cit320","first-page":"A96","article-title":"Efficacy of the angiotensin receptor blocker losartan during high potassium intake in CKD patients [abstract no: FP158]","volume":"34","author":"Wouda","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0321|cit321","first-page":"15","article-title":"Diminished efficacy of the angiotensin receptor blocker losartan during high potassium intake in CKD patients [abstract no: TH-OR056]","volume":"30","author":"Wouda","year":"2019","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/ckj\/sfab031","article-title":"Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD","volume":"14","author":"Wouda","year":"2021","journal-title":"Clinical Kidney Journal"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jch.12021","article-title":"Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern","volume":"15","author":"Wang","year":"2013","journal-title":"Journal of Clinical Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/hr.2012.184","article-title":"The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease","volume":"36","author":"Yanagi","year":"2013","journal-title":"Hypertension Research - Clinical & Experimental"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD007751.pub3-BIB0325|cit325","first-page":"501A","article-title":"Beneficial effects of ARB olmesartan on ambulatory blood pressure profile and renal function in hypertensive patients with CKD [abstract no: F-PO1694]","volume":"21","author":"Yanagi","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000438460","article-title":"Estimated glomerular filtration rate variability independently predicts renal prognosis in advanced chronic kidney disease patients","volume":"130","author":"Uehara","year":"2015","journal-title":"Nephron"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/hr.2012.183","article-title":"Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT)","volume":"36","author":"Yasuda","year":"2013","journal-title":"Hypertension Research - Clinical & Experimental"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0328|cit328","unstructured":"Yildiz A Azamir M Erkoc R Kayacan SM Tukek T Gorcin B The comparison of enalapril and losartan treatment in patients with moderate chronic renal failure [abstract] 36th Congress. European Renal Association. European Dialysis and Transplantation Association; 1999 Sept 5-8; Madrid, Spain 1999 162"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000107410","article-title":"Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan","volume":"25","author":"Yilmaz","year":"2007","journal-title":"Blood Purification"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0330|cit330","unstructured":"Telmisartan versus enalapril in heart failure with reduced ejection fraction patients with moderately impaired kidney functions www.clinicaltrials.gov\/show\/NCT04736329 2021"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0331|cit331","unstructured":"Losartan and uric acid metabolism in children with proteinuric nephropathies www.clinicaltrials.gov\/show\/NCT05402397 2022"},{"issue":"7","key":"10.1002\/14651858.CD007751.pub3-BIB0332|cit332","doi-asserted-by":"publisher","first-page":"121-8","DOI":"10.15829\/1728-8800-2021-3078","article-title":"Effect of angiotensin II receptor blocker therapy on markers of fibrosis and immune inflammation in hypertensive patients with chronic kidney disease after ischemic stroke","volume":"20","author":"Osipova","year":"2021","journal-title":"Cardiovascular Therapy & Prevention (Russian Federation)"},{"issue":"Sept","key":"10.1002\/14651858.CD007751.pub3-BIB0333|cit333","first-page":"77a","article-title":"Relevance of BP control and angiotensin II blockade in controlling proteinuria [abstract no: A0417]","volume":"11","author":"Segna","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3317\/jraas.2003.007","article-title":"Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses","volume":"4","author":"Segura","year":"2003","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD007751.pub3-BIB0335|cit335","first-page":"411a","article-title":"The impact of the combination of losartan and enalapril on erythropoiesis in Japanese patients with chronic glomerulonephritis (cgn) [abstract]","volume":"12","author":"Shoji","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD007751.pub3-BIB0336|cit336","first-page":"773a","article-title":"The long term influence of the combination of losartan and enalapril on erythropoiesis in Japanese patients with chronic glomerulonephritis. [abstract no: SU-PO1080]","volume":"14","author":"Shoji","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD007751.pub3-BIB0337|cit337","first-page":"672","article-title":"Effects of candesartan on renal and cardiovascular outcomes in hypertensive patients with renal impairment [abstract no: SU-PO633]","volume":"14","author":"Suzuki","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0338|cit338","unstructured":"Comparison of efficacy in renoprotection between azilsartan medoxomil and enalapril: a randomized, open-labeled controlled trial www.trialsearch.who.int\/Trial2.aspx?TrialID=TCTR20220426002 2022"},{"issue":"9489","key":"10.1002\/14651858.CD007751.pub3-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD007751.pub3-BIB0340|cit340","first-page":"161","article-title":"Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004","volume":"56","author":"Centers for Disease Control and Prevention (CDC)","year":"2007","journal-title":"MMWR - Morbidity & Mortality Weekly Report"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/ajkd.2001.26833","article-title":"The timing of nephrologist referral and arteriovenous access use: the CHOICE study","volume":"38","author":"Astor","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007751.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1681\/ASN.2004070539","article-title":"Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000","volume":"16","author":"Coresh","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0343|cit343","first-page":"ix19","article-title":"Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease","volume":"22 Suppl 9","author":"Daly","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1440-1797.2005.00433.x","article-title":"Effects of late referral to a nephrologist in patients with chronic renal failure","volume":"10","author":"Dogan","year":"2005","journal-title":"Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0272-6386(03)00916-8","article-title":"A population-based study of the incidence and outcomes of diagnosed chronic kidney disease","volume":"42","author":"Drey","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-127-5-199709010-00001","article-title":"Effect of angiotensin converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group","volume":"127","author":"Giatras","year":"1997","journal-title":"Annals of Internal Medicine"},{"issue":"7650","key":"10.1002\/14651858.CD007751.pub3-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD007751.pub3-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7577","key":"10.1002\/14651858.CD007751.pub3-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/bmj.39001.657755.BE","article-title":"Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey","volume":"333","author":"Hallan","year":"2006","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD007751.pub3-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0353|cit353","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0354|cit354","first-page":"145","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [Erratum in: 2000 May 4;342(18):1376] [Erratum in: N Engl J Med 2000 Mar 9;342(10):748]","volume":"342","author":"Yusuf","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10157-007-0463-x","article-title":"Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient","volume":"11","author":"Imai","year":"2007","journal-title":"Clinical & Experimental Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition: proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.ajkd.2003.12.046","article-title":"Unreferred chronic kidney disease: a longitudinal study","volume":"43","author":"John","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD007751.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2753.2007.00883.x","article-title":"Economic burden of chronic kidney disease","volume":"14","author":"Khan","year":"2007","journal-title":"Journal of Evaluation in Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD007751.pub3-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7326\/0003-4819-137-6-200209170-00007","article-title":"The timing of specialist evaluation in chronic kidney disease and mortality","volume":"137","author":"Kinchen","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0272-6386(00)70018-7","article-title":"Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials","volume":"35","author":"Kshirsagar","year":"2000","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0362|cit362","volume-title":"Kumar & Clark clinical medicine","author":"Kumar","year":"2002"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"9311","key":"10.1002\/14651858.CD007751.pub3-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0735-1097(00)00736-1","article-title":"Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril","volume":"36","author":"MacMahon","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0367|cit367","first-page":"ix26","article-title":"How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease","volume":"22 Suppl 9","author":"Metcalfe","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0368|cit368","unstructured":"National Institute for Health and Clinical Excellence Early identification and management of chronic kidney disease in adults in primary and secondary care. 2008 http:\/\/guidance.nice.org.uk\/CG73"},{"issue":"9287","key":"10.1002\/14651858.CD007751.pub3-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin-angiotensin-aldosterone system and progression of renal disease","volume":"17","author":"Ruster","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"15","key":"10.1002\/14651858.CD007751.pub3-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","article-title":"Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin\/Enalapril Coronary Atherosclerosis Trial (SCAT)","volume":"102","author":"Teo","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0372|cit372","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0373|cit373","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"575","key":"10.1002\/14651858.CD007751.pub3-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.3399\/bjgp10X502173","article-title":"Does stage-3 chronic kidney disease matter? A systematic literature review","volume":"60","author":"Sharma","year":"2010","journal-title":"British Journal of General Practice"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0375|cit375","unstructured":"Scottish Intercollegiate Guidelines Network Diagnosis and management of chronic kidney disease. 2008 www.sign.ac.uk\/guidelines\/fulltext\/103\/index.html"},{"key":"10.1002\/14651858.CD007751.pub3-BIB0376|cit376","unstructured":"The SONG Handbook Version 1.0, 2017 songinitiative.org\/reports-and-publications\/"},{"issue":"11","key":"10.1002\/14651858.CD007751.pub3-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the Kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007751.pub3-BIB0378|cit378","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006257","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","author":"Strippoli","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007751.pub3-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007751.pub3-BIB0380|cit380","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007751","article-title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non-diabetic chronic kidney disease","author":"Blackburn","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD007751.pub3-BIB0381|cit381","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007751.pub2","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease","author":"Sharma","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:41:45Z","timestamp":1730306505000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007751.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":381,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007751.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}